Australian Doctor Australian Doctor 12 May 2017 | Page 27

“Dosing frequency,
what do you prefer?”
Not a real doctor or patient
Y
A
D
-
A
-
E
C
N
O
.
BREO ELLIPTA T OF THE WAY.
AND OU
®
®
fluticasone furoate
vilanterol
1
/
Guidelines advise all patients with asthma to carry a reliever containing a rapid onset ß 2 -agonist at all times. For patients on Breo Ellipta ,
that could be salbutamol e.g. Ventolin .
®
®
® 2
Breo ® Ellipta ® is indicated for the regular treatment of moderate to severe asthma in patients (≥12 years of age) who require a medium to high dose ICS with a
LABA. 1 Prescribers should note that 100 mcg of fluticasone furoate (FF) is a medium dose of ICS and 200 mcg of FF is a high dose of ICS. To minimise the adverse
reactions, inhaled corticosteroids should be used at the lowest dose that maintains symptom control. 1
ICS = inhaled corticosteroid; LABA = long acting ß 2 -agonist. References: 1. Breo Ellipta Product Information. 2. National Asthma Council Australia. Australian Asthma Handbook, Version 1.1. National Asthma Council Australia, Melbourne, 2015.
Website. Available from: http://www.asthmahandbook.org.au. Accessed July 2016.
Before prescribing please review PBS and Product Information available in the primary advertisement in this publication.
For full product information please contact GlaxoSmithKline Australia Pty Ltd. PO Box 18095, Melbourne, VIC 8003. ABN 47 100 162 481.
For information regarding a GSK product or to report an adverse event, please contact Medical Information on 1800 033 109.
Breo ®, Ellipta ® and Ventolin ® are registered trade marks of the GSK group of companies. Breo ® Ellipta ® was developed in collaboration with Innoviva.
AUS/FFT/0002/17 Date of Approval: January 2017 S&H GSKBR0125-AD-FP-SA-B